1986
DOI: 10.1016/0014-2999(86)90690-4
|View full text |Cite
|
Sign up to set email alerts
|

Platelet activating factor-induced ischemic bowel necrosis: The effect of PAF antagonists

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
24
0

Year Published

1987
1987
2010
2010

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 60 publications
(24 citation statements)
references
References 5 publications
0
24
0
Order By: Relevance
“…the PAF degrading enzyme) in premature neonates suggests a role for this molecule in NEC pathogenesis. Initial studies in adult rats using an acute model have shown that exogenous PAF given intravenously results in ischemic bowel necrosis (11) and endotoxin, hypoxia, or tumor necrosis factor (TNF)-induced intestinal injury can be prevented by PAF receptor (PAFR) antagonists (12,13 …”
mentioning
confidence: 99%
“…the PAF degrading enzyme) in premature neonates suggests a role for this molecule in NEC pathogenesis. Initial studies in adult rats using an acute model have shown that exogenous PAF given intravenously results in ischemic bowel necrosis (11) and endotoxin, hypoxia, or tumor necrosis factor (TNF)-induced intestinal injury can be prevented by PAF receptor (PAFR) antagonists (12,13 …”
mentioning
confidence: 99%
“…The intravenous administration of PAF into the descending aorta of adult rats results in lesions limited to the intestine that are morphologically identical to the lesions of ischemic necrosis seen in human NEC [8]. The injurious effect of PAF on the intestine is enhanced by the addition of endotoxin, and high-dose endotoxin alone results in intestinal injury that can be prevented with PAF receptor antagonists [16]. This endotoxin-induced intestinal injury has been shown to be associated with increased endogenous PAF production in intestinal homogenate [6].…”
Section: Discussionmentioning
confidence: 97%
“…For example, ONO-6240 is significantly less potent as an antagonist of PAF binding to human platelets than to human neutrophils [1], and at 0.3 mg/kg ONO-6240 attenuated PAF-induced intestinal damage, but did not prevent PAF-induced neutrophilia [2]. Similarly, BN-52021 inhibited eicosanoid release in the perfused, isolated rat stomach, while producing only slight changes in the perfusion rate [3].…”
Section: Introductionmentioning
confidence: 96%